Samsung Biologics to Participate in BIOPLUS-INTERPHEX KOREA 2025

[Financial News] Samsung Biologics announced on the 14th that it will participate in South Korea’s largest comprehensive pharmaceutical and biotech convention, BIOPLUS-INTERPHEX KOREA 2025 (BIX 2025).
BIX is the nation’s largest global pharmaceutical and biotech exhibition, hosted by the Korea Biotechnology Industry Organization (KBIO) and organized by RX Korea.
This event serves as a platform for sharing the latest technologies and industry trends, as well as fostering partnerships through business networking. This year, it will be held from July 15 to 17 at COEX in Samseong-dong, Seoul. Approximately 300 companies and over 12,000 attendees are expected to visit the venue.
Samsung Biologics will set up a solo booth for the second consecutive year.
At the booth, a wall graphic will showcase the company’s unrivaled manufacturing capacity, which is expected to reach 1,324,000 liters by 2032. The display will also highlight Samsung Organoid, the contract development (CDO) platform, next-generation modality service capabilities, and the company’s end-to-end services spanning from contract research (CRO) to contract manufacturing (CMO).
This year, the booth will actively promote the newly launched CMO brand, ExellenS. ExellenS embodies a manufacturing system that prioritizes equivalence and speed, aiming to deliver consistently high-quality pharmaceuticals to clients quickly.
On the second day of the event, July 16, Samsung Biologics will hold a session highlighting the competitiveness of its CDO services. Lee Tae-hee, Head of Antibody Culture PD Team (Executive Director), will present strategies to accelerate clients’ drug development timelines under the theme, 'Accelerating Drug Development: From Feasibility Assessment to IND Submission.'
During the event, Samsung Biologics will also conduct sponsorship activities to boost brand awareness. Hanging banners will be installed above the booth and floor banners below, aiming to enhance recognition of the company’s vision and service competitiveness.
Meanwhile, Samsung Biologics has been continuously expanding its engagement with existing and potential clients by participating in various global conferences throughout the year.
Earlier this year, the company met with numerous clients at the BIO International Convention (BIO) in June and BioJapan in October. At the end of October, Samsung Biologics plans to further strengthen its order activities by participating in CPhI Worldwide, Europe’s largest pharmaceutical and biotech conference, held in Frankfurt, Germany.

vrdw88@fnnews.com Kang Jung-mo Reporter